PhenomeX Inc

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PhenomeX is enabling researchers to take advantage of each cell's full potential and launch the next phase of functional cell biology that will improve human health. We give researchers the most thorough understanding of how cells function and a detailed picture of each cell's behaviour.

EMERYVILLE, Calif. , Sept. 27, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the Beacon® optofluidic platform.

PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform

Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif. , Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023.

PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

New Beacon platform data to be presented by Genovac at Discovery on Target 2023 Poster and podium presentation featuring the Beacon platform to be presented at Annual Festival of Biologics Basel Conference & Exhibition EMERYVILLE, Calif. , Sept. 20, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming cell biology conferences.

PhenomeX to Participate in Upcoming Cell Biology Conferences

Fully quantitative bulk and comprehensive single cell proteomics are now both available on the IsoSpark platform  EMERYVILLE, Calif. , Sept. 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Meteor™ chips on the IsoSpark™ platform, providing a significant advancement in high throughput, quantitative, fully automated, multiplexed bulk proteomics.

PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Bruker

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PhenomeX Inc. (NasdaqGS: CELL) to Bruker Corporation (NasdaqGS: BRKR). Under the terms of the proposed transaction, shareholders of PhenomeX will receive only $1.00 in cash for each share of PhenomeX that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.

PHENOMEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PhenomeX Inc. - CELL

EMERYVILLE, Calif. , Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for $1.00 per share.

PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of PhenomeX Inc. (NASDAQ: CELL) to Bruker Corporation for $1.00 per share is fair to PhenomeX shareholders. Halper Sadeh encourages PhenomeX shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether PhenomeX and its board o.

CELL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of PhenomeX Inc. Is Fair to Shareholders

MILWAUKEE , Aug. 17, 2023 /PRNewswire/ -- Ademi LLP is investigating PhenomeX (NASDAQ: CELL) for possible breaches of fiduciary duty and other violations of law in its transaction with Bruker Corporation. Click here to learn how to join the action https://www.ademilaw.com/case/phenomex-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether PhenomeX Inc. has obtained a Fair Price in its transaction with Bruker Corporation

PhenomeX Inc. CELL, +137.43% stock has more than doubled on Thursday after Bruker Corp. BRKR, -2.56% said it would acquire the Emeryville, Calif.-based, cell biology company for $1 a share in a deal that values the company at $108 million.

PhenomeX stock rallies by 137% after buyout offer from Bruker

BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)-- #BRKR--Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction. The proposed acquisition values PhenomeX at a total equity value of approximately $108 million. PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular functi.

Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction

Strategic Alternatives Process Continuing; Board Focused on Maximizing Stockholder Value EMERYVILLE, Calif. , Aug. 14, 2023 /PRNewswire/ -- PhenomeX, Inc. (Nasdaq: CELL), a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023.

PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business Update

EMERYVILLE, Calif. , Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023.

PhenomeX to Report Second Quarter 2023 Financial Results on August 14, 2023

PhenomeX stands behind its ground-breaking Beacon® technology that advances human health globally; remains confident it will prove its case in court EMERYVILLE, Calif. , Aug. 7, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the series of lawsuits filed by AbCellera in 2020 will now proceed in litigation.

PhenomeX Announces Lifting of the Stay in AbCellera Patent Infringement Case

EMERYVILLE, Calif. , June 13, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate.

PhenomeX's Beacon® Technology Enables Early Identification of Potent Omicron-Neutralizing Antibodies

Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T Cell profiling, for precision immunotherapy translational research and accelerated development EMERYVILLE, Calif. , June 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of the Beacon Quest™ optofluidic system, with Opto® T Cell Profiling workflows for immunotherapy translational research and a platform price under $1 million USD, less than half of the higher-throughput Beacon system, enabling broader accessibility to the cutting-edge technology critical for next-generation precision medicine.

PhenomeX Launches Beacon Quest™ Optofluidic System with Opto® T Cell Profiling Workflows

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities EMERYVILLE, Calif. , May 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery.

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

PhenomeX Inc. (CELL) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.32 per share a year ago.

PhenomeX Inc. (CELL) Reports Q1 Loss, Lags Revenue Estimates

Company provides full year 2023 financial guidance EMERYVILLE, Calif. , May 11, 2023 /PRNewswire/ -- PhenomeX, Inc. (Nasdaq: CELL), a life sciences tools company, today reported financial results for the first quarter ended March 31, 2023.

PhenomeX Reports First Quarter 2023 Financial Results

PhenomeX optofluidic and proteomic technology to be featured in several poster and podium presentations EMERYVILLE, Calif. , May 11, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that it will participate in the 19th annual Protein Engineering & Cell Therapy Summit (PEGS) Conference and Expo being held from May 15-19 at the Hynes Convention Center in Boston, Mass.

PhenomeX To Participate in 19th Annual PEGS Boston Conference & Expo

EMERYVILLE, Calif. , April 27, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the first quarter 2023 after market on Thursday, May 11, 2023.

PhenomeX to Report First Quarter 2023 Financial Results on May 11, 2023

EMERYVILLE, Calif. , April 10, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.

PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors

EMERYVILLE, Calif., April 7, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation at the American Association of Cancer Research (AACR) Annual Meeting 2023 being held from April 14-19 at the Orange County Convention Center in Orlando, Fla. AACR brings together scientists, clinicians, other health care professionals, survivors, patients, and advocates to share the latest advances in cancer science and medicine through this year's meeting theme of "Advancing the Frontiers of Cancer Science and Medicine."

News for PhenomeX Inc Stock (CELL)